Identification and Characterisation of Minimal Residual Disease in Solid Tumors

Acta Medica Austriaca

Volumn 27, Issue 5, 2000, Pages 8-12

  Pantel, K ^a   Otte, M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cytokeratin; Immunohistochemistry; Minimal residual disease; RT PCR

Indexed keywords

TUMOR MARKER;

BONE MARROW; GENETICS; HUMAN; LIVER; LYMPH NODE; METASTASIS; MINIMAL RESIDUAL DISEASE; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR EMBOLISM;

BONE MARROW; HUMANS; LIVER; LYMPH NODES; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; NEOPLASM, RESIDUAL; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 0034573015     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Bostick PJ, Chatterjee S, Chi DD, Huvnh KT, Gmliano AE, Cote R, Hoon DS: Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the Iymph nodes and blood of breast cancer patients. J clin Oncol 1998:16:2632-2640.
2. Braun S, Pantel K, Müller P, Janni W, Hepp F, Kentenich Ch. Gastroph S, Wischnik A, Dimpfel T, Kindermann G, Riethmuller G, Schlimok G: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I. II. or III breast cancer. N Engl J Med 2000;342:525-533.
3. Braun S, Kentenich ChRM, Janni W, Hepp F, de Waal J, Willegroth F, Sommer HL, Panlel K: Lack of effect of adjuvant chemotherapy on the elimination of single dormant cells in bone marrow of high risk breast cancer patients. J Clin Oncol 2000;18:80-86.
4. Braun S, Hepp F, Kentenich ChRM, Janni W, Pantel K, Riethmüller G, Sommer HL, Monoclonal antibody therapy with Erecolomab in breast cancer patients Monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res 1999;5:3999-4004.
5. Braun S, Müller M, Hepp F, Schlimok G, Rtethmüller G, Pantel K: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1998;90:1099-1100.
6. Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad Ø, Diel I. Solomayer EF, Theocharous P, Coombes RC, Smith BM, Wunder E, Marolleau JP, Garcia J, Pantel K: Standardization of the immunocytochemical detection of cancer cells in BM and blood: 1. establishment of objective criteria for the evaluation of immunostationed cells Cytotherapy 1999;1: 377-388.
7. Burkhardt R, Fnsch B, Kettner G: The clinical study of micrometastatic cancer by bone biopsy. Bull Cancer 1980;67:291-305.
8. Cote RJ, Rosen PP, Lesser ML, Old MP: Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991;9:1749-1756.
9. Cote RJ, Beattie EJ, Clraiwun B, Shi SR, Harvey J, Chen SC, Sherrod AE, Groshen S, Taylor CR: Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg 1995;222:415-425.
10. Denis MG, Tessier MH, Dréno B, Lustenberger P: Circulating micrometastases following oncological surgery. The Lancet 1996;347:913.
11. Diel IJ, Kaufmann M, Costa SD, Holle R, von Mickwitz G, Solomayer EF, Kaul S, Bastert G: Micrometastatic breast cancer cells in bone marrow at primary surgery, prognostic value in comparison with nodal status. J Natl Cancer Inst 1996:88:1652-1658.
12. Dietmaier W, Hartmann A, Wallinger S, Heinmoller E, Kerner T, Endl E, Jauch KW, Hofstadter F, Rüschoff J: Multiple mutation analysis in single tumor cells with improved whole genome amplification. Am J Pathol 1999; 154:83-95
13. Eschwège P, Dumas F, Blanchet P, LeMaire V, Benoit G, Jardin A, Lacour B, Loric S: Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 1995;346:1528-1530.
14. Fields KK, Elfenbein GJ, Trudeau WL, Perkins JB, Janssen WE, Moscinski LC: Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996;14:1868-1876.
15. Funke I, Schraut W: Meta-analyses of studies on hone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol 1998;16:557-566.
16. Hansen E, Wolff N, Knuechel R, Ruschoff J, Hofstaedter F, Taeger K: Tumor cells in blood shed from the surgical field. Arch Surg 1995;130:387-393.
17. Harbeck N, Untch M, Pache L, Eiermann W:Tumor cell detection in the bone marrow of breast cancer patients at primary therapy, results of a 3-year median folios up Br J Cancer 1994;69:566-571.
18. Hayashi N, Ito I, Yanagisawa A, Kato Y, Nakamori S, Imaoka S, Watanabe H, Ogawa M, Nakamura K: Genetic diagnosis of lymph-node metastasis in colorectal cancer. The Lancet 1995;345:1257-1259.
19. Hainmerling G, Maschek V, Slurmhöfel K, Momburg F: Regulation and functional role of MHC expression on tumors. In: Melchers F(ed): Progression in Immunologv Berlin. Springer. 1989. pp 1071-1078.
20. Heiss MM, AIIgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW: Individual development and uPA-receptor expression of disseminated tumor cells in bone marrow: A reference to early systemic disease in solid cancer. Nature Medicine 1995;1:1035-1039.
21. Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, Passhck B, Broelsch CE. K, Pantel K: Prognostic value of immunohisloche- mically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997;337:1188-1194.
22. Jauch KW, Heiss MM, Grueizner U, Funke I, Pantel K, Babic R, Eissner HJ, Riethmueller G, Schildberg FW: Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J Chn Oncol 1996;14:1810-1817.
23. Klein ChA. Schrmdt-Kittler O, Schradt JA, Pantel K, Speicher MR, Riehmuller G: Comparative genomic hybridization, loss of heterozygocity and DNA sequence analysis of single cells. Proc Natl Acad Sci USA 1999;96:4494-4499.
24. Krismann M, Todt B, Schröder J, Gareis D, Müller KM, Seeber S, Schutte J: Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol 1995;13:2769-2775.
25. Kubuschok B, Passlick B, Izbicki J, Thetter O, Pamel K: Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small cell lung cancer. J Clin Oncol 1999;17:24.
26. Liefers GJ, Cleton JA, Hermans d van VJ, van-Krieken JH, Cornelisse CJ, Tollenaar RA: Micrometastases and survival in stage II colorectal cancer see comments. N Engl J Med 1998;339:223-228.
27. Lindemann F. Schlimok G, Dirschedl P, Witte J, Riethmüller G: Prognostic significance of micrometastic tumor cells in bone marrow of colorectal cancer patients. Lancet 1992;340:685-689.
28. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC: Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 1999;354:197-202.
29. Martin VM, Siewert C, Scharl A, Harms T, Heinze R, Ohl S, Radbruch A, Milwnyi S, Schmitz J: Immunomagnetic enrichment of disseminated epithelial tumor cells from peripheral blood by MACS. Exp Hematol 1998; 26:252-264.
30. Muller P, Weckermann D, Riethmüller G, Schlimok G: Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. Cancer Genet. Cytogenet 1996;88:8-16.
31. Naume B, Borgen E, Beiske K, Herstad TK, Ravnas G, Renolen A, Trachsel S, Thrane-Stehen K, Funderud S, Kvalheim G: Detection of isolated breast carcinoma cells in peripheral blood or bone marrow by immunomagnetic techniques. J Hematother 1997;6:103-111.
32. Neumaier M, Gerhard M, Wagener C: Diagnosis of micrometastases by the amplification of tissue-specific genes. Gene 1995;159:43-47.
33. Offner S, Schmaus W, Witter K, Baretten GK, Schlimok G, Passlick B, Riethmüller G, Pantel K: p53 gene mutations are not required for early dissemination of cancer cells. Proc Natl Acad Sci USA 1999;96:6942-6946.
34. Ohgami A, Mitsudomi T, Sugio K, Tsuda T, Oyama T, Nishida K, Osaki T, Yasumoto K: Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. Ann Thorac Surg 1997;64:363-367.
35. Osborne MP, Rosen PP: Detection and management of bone marrow micrometastases in breast cancer. Oncology 1994;8:25-36.
36. Pantel K, Dickmanns A, Zippehus A, Klein C, Shi J, Hoechtlen-Vollmar W, Schlimok G, Weckermann D, R. Oberneder R, Fanning E, Riethmüller G: Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Nat Cancer Inst 1995;87:1162-1168.
37. Pantel K, Izbicki J, Passlick B, Angstwurm M, Häussinger K, Thetter O, Riethmuller G: Prognostic significance of isolated tumor cells in bone marrow of patients with non-small cell carcinomas without overt metastases. Lancet 1996;347:649-653.
38. Pantel K, Enzmann T, Kollermann J, Caprano J. Riethmuller G, Kollermann MW: Immunocytochemical monitoring of micrometastatic disease: reduction of prostate cancer cells in bone marrow by androgen deprivation. Int J Cancer 1997;71:521-525.
39. Pantel K, Schlimok G, Angstwurm M, Weckermann C, Schmaus W, Gath H, Pasblick B, Izbicki J, Riethmuller G: Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow J Hematother 1994;3:165-173.
40. Pamel K, Schlimok G, Braun S, Kutter D, Schaller G, Funke I, Izbicki J, Riethmüller G: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85:1419-1424
41. Pantel K, Cote RJ, Fodstad: Detection and clinical importance of micrometastatic disease J Natl Cancer Inst 1999;91:1113-1124.
42. Pardoll DM, Cancer vaccines. Immunol Today 1993;14:310-316.
43. Passlick B, Izbicki JR, Kubuschok B, Nathrath W, Thener O, Pichelmeter U, Schweiberer L, Riethmüller G, Pantel K: Immunhistochemical assessment of individual tumor cells in lymph nodes of patients with non-small cell lung cancer. J Clin Oncol 1994;12:1827-1832.
44. Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichelmaier H, Hirche H, Buggisch P, Witte J, Pichelmayer R: Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16:1788-1794.
45. Schlimok G, Funke I, Pantel K, Strobel F, Lindemann F, Witte J, Riethmuller G: Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer 1991;27:1461-1465.
46. Schlimok G: Mikrometastasen epithelialer Tumoren im Knochenmark: Immunzytochemischer Nachweis und in vivo Markierung mit Hilfe monoklonaler Antikörper. Habilitation 1988. Ludwig-Maximilians-Universität München, 1988.
47. Schlimok G, Funke I, Holzmann B, Göttlinger HG, Schmidt G, Hauser H, Swierkoi S, Warnecke HH, Schneider B, Koprowski H, Riethmüller G. Micrometastatic cancer cells in bone marrow: in vitro detection with anticytokeratin and in vivo labeling with anti-17-IA monoclonal antibodies. Proc Natl Acad Sci USA 1987;84:8672-8676.
48. Soeth E, Vogel I, Röder C, Juhl H, Marxsen J, Krüger U, Henne-Bruns D, Kremer B, Kalthoff H: Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res 1997; 57:3106-3110.
49. Sidransky D: Nucleic acid-based methods for the detection of cancer. Science 1997:278:1054-1059.
50. Tada M, Omata M, Kawai SH, Saisho H, Ohio M, Saiki RK, Sninsky JJ: Detection of ras gene mutations in Pancreatic Juice and Peripheral Blood of patients with pancrealic adenocarcinoma Cancer Res 1993;53:2472-2474.
51. Traweek ST, Liu J, Battifora H: Keratin gene expression in non-epithelial tissues. Detection with polymerase chain reaction Am J Pathol 1993; 142:1111-1118.
52. Thorban S, Roder JD, Nekarda H, Funk J, Siewert R, Pantel K: Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. J Natl. Cancer Inst. 88. 1222-7 (1996).
53. Wallich R, Bulbue N, Hammerlmg GJ, Katzav S, Sagl S, Feldman M: Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 1985;315:301-305.
54. Weitz J, Kienle P, Lacroix J, Willeke F, Benner A, Lehnen T, Herfarth C. von-Knebel-Doebentz M: Dissemination of tumor cells in patients under-going surgery for colorectal cancer. Clin Cancer Res 1998;4:343-348.
55. Zippelius A, Kufer P, Honold G, Riethmüller G: Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 1997:15:2701-2708.